Institute News
Most Popular
Free community webinar about MacTel
November 14, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database. Neurotech has partnered with Prevent Blindness to sponsor an online event with a focus on MacTel Type 2. This free webinar...
What To Expect in a MacTel Imaging Exam
April 29, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database. This post will explain some (but not all) of the imaging exams that your eye doctor may perform during a screening or follow up...
The Latest MacTel Research: What does it mean for patients?
Scientists at the Lowy Medical Research Institute and their collaborators recently published an article describing a role for serine and toxic lipids in macular telangiectasia type 2. The article, “Serine and Lipid Metabolism in Macular Disease and...
CNTF Clinical Trials: COVID-19 Update
March 24, 2020 The rapid spread of COVID-19 has disrupted many standard clinical operations, including the LMRI/Neurotech Phase 1, 2, and 3 clinical trials testing CNTF in MacTel. If you have questions regarding upcoming appointments or other study-...
MacTel Project 2023 Annual Meeting Summary
February 6, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database. The MacTel Project is an international research effort whose goal is to find the causes of, and treatments for, macular telan...
MacTel SAFE Study
March 6, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database. LMRI is conducting the SAFE study (Phase 2a Study of the Effect of Serine Supplementation and Fenofibrate Treatment on Serum...
2018 MacTel Project Annual Summary
The Lowy Medical Research Institute would like to announce the latest MacTel Project Newsletter, which contains important updates on the Natural History Observation and Registry (NHOR) Study, Clinical Trials, and MacTel Projects.
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)
LMRI would like to share the following press release from Neurotech Pharmaceuticals about the BLA for NT-501 as a treatement for MacTel: Cumberland, R.I., November 8, 2024 (BUSINESS WIRE) – Neurotech Pharmaceuticals, Inc., an innovator in sustained...
MacTel Project 2021 Update
LOWY MEDICAL RESEARCH INSTITUTE - LMRI This past year has surely been an interesting and challenging one. We hope that you and your family, friends, neighbors, and coworkers were able to weather the events safely. Despite the many challenges prese...